Celldex Therapeutics Inc (CLDX) Implied Volatility Current

Tracking CLDX implied volatility helps you identify when options premiums on Celldex Therapeutics Inc are historically cheap or expensive, and where the best trades are hiding. Celldex Therapeutics Inc implied volatility reflects the market's expectation of future price movement: when CLDX IV rises, option premiums increase, creating opportunities for sellers, and when it drops, buyers can find cheaper contracts. Use our scanner to monitor Celldex Therapeutics Inc's implied volatility current levels in real time and filter for high-probability trades.

Implied volatility is derived from option prices using models like Black-Scholes and represents the annualized expected move of an underlying stock. For CLDX, tracking metrics like CLDX IV rank helps traders understand whether current implied volatility is historically high or low. IV rank compares today's reading against the past year's range — a high rank on CLDX signals rich premiums and potential mean-reversion, while a low rank may favor long options strategies.

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation.

The company has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. Celldex Therapeutics, Inc. was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Premium sellers, directional traders, and spread builders all need the same starting point: a clear read on where CLDX implied volatility sits today versus where it has been. Our scanner ranks Celldex Therapeutics Inc implied volatility against its historical range, surfaces extremes in CLDX IV rank, and pairs every reading with the trades that exploit it. Stop guessing whether Celldex Therapeutics Inc IV is rich or cheap — measure it, then act on it.